An Open-label, Parallel-group Study to Assess the Effect of LIK066 on Urinary Glucose Excretion, Pharmacokinetics, Safety and Tolerability Following Multiple Dose Administration in Patients With Decreased Renal Function Compared to Subjects With Normal Renal Function
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Licogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 06 Feb 2018 Status changed from recruiting to completed.
- 16 Oct 2017 Planned End Date changed from 14 Feb 2018 to 7 Nov 2017.
- 16 Oct 2017 Planned primary completion date changed from 14 Feb 2018 to 7 Nov 2017.